WO2007016099A3 - Protection of transplanted stem cells with hmg-coa reductase inhibitors - Google Patents

Protection of transplanted stem cells with hmg-coa reductase inhibitors Download PDF

Info

Publication number
WO2007016099A3
WO2007016099A3 PCT/US2006/028860 US2006028860W WO2007016099A3 WO 2007016099 A3 WO2007016099 A3 WO 2007016099A3 US 2006028860 W US2006028860 W US 2006028860W WO 2007016099 A3 WO2007016099 A3 WO 2007016099A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
coa reductase
reductase inhibitors
protection
stem cells
Prior art date
Application number
PCT/US2006/028860
Other languages
French (fr)
Other versions
WO2007016099A2 (en
Inventor
Inderjit Singh
Avtar K Singh
Original Assignee
Musc Found For Res Dev
Inderjit Singh
Avtar K Singh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev, Inderjit Singh, Avtar K Singh filed Critical Musc Found For Res Dev
Publication of WO2007016099A2 publication Critical patent/WO2007016099A2/en
Publication of WO2007016099A3 publication Critical patent/WO2007016099A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Abstract

Impaired remyeliiiation due to degeneration of both postmitotic oligodendrocytes and oligodendrocyte progenitors (OPs) is the major hallmark of inflammatory demyelination in multiple sclerosis (MS) lesions and other inflammatory diseases. HMG-CoA reductase inhibitors also are proposed to stimulate and protect stems cells, such as OPs, for example in the context of transplantation.
PCT/US2006/028860 2005-07-29 2006-07-26 Protection of transplanted stem cells with hmg-coa reductase inhibitors WO2007016099A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70412905P 2005-07-29 2005-07-29
US60/704,129 2005-07-29

Publications (2)

Publication Number Publication Date
WO2007016099A2 WO2007016099A2 (en) 2007-02-08
WO2007016099A3 true WO2007016099A3 (en) 2007-08-16

Family

ID=37709122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/028860 WO2007016099A2 (en) 2005-07-29 2006-07-26 Protection of transplanted stem cells with hmg-coa reductase inhibitors

Country Status (1)

Country Link
WO (1) WO2007016099A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI121073B (en) * 2008-10-15 2010-06-30 Suomen Punainen Risti Veripalv Method of protecting cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669886B1 (en) * 2000-08-03 2003-12-30 Scimed Life Systems, Inc. Reinforced catheter and method of manufacture
US20040209847A1 (en) * 2003-01-23 2004-10-21 Dasseux Jean-Louis Henri Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
US6808702B2 (en) * 2000-04-13 2004-10-26 Board Of Regents, The University Of Texas System Treatment of disorders by implanting stem cells and/or progeny thereof into gastrointestinal organs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6808702B2 (en) * 2000-04-13 2004-10-26 Board Of Regents, The University Of Texas System Treatment of disorders by implanting stem cells and/or progeny thereof into gastrointestinal organs
US6669886B1 (en) * 2000-08-03 2003-12-30 Scimed Life Systems, Inc. Reinforced catheter and method of manufacture
US20040209847A1 (en) * 2003-01-23 2004-10-21 Dasseux Jean-Louis Henri Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

Also Published As

Publication number Publication date
WO2007016099A2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2006044204A3 (en) Neuronal progenitors from feeder-free human embryonic stem cell culture
WO2005084223A3 (en) Methods and compositions for hair growth
WO2001011011A3 (en) Multipotent adult stem cells and methods for isolation
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2004113513A3 (en) Methods and compositions for modulating stem cell growth and differentiation
WO2007008758A3 (en) Methods for identifying agents and conditions that modulate neurogenesis
WO2006004910A3 (en) Improved bispecific antibodies
WO2004090140A3 (en) Methods and means for increasing the tolerance of plants to stress conditions
WO2006052767A3 (en) Compositions and methods for stabilizing liposomal camptothecin formulations
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2006118914A3 (en) Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
EP2048227A3 (en) Methods for proliferating stem cells
WO2006094286A3 (en) Adult pancreatic derived stromal cells
WO2009045360A3 (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2007075895A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2006034235A3 (en) Substituted quinoline and quinazoline inhibitors of quinone reductase 2
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
WO2006069719A3 (en) Lyophilization of virosomes
WO2003089619A3 (en) Placental derived stem cells and uses thereof
WO2007112138A3 (en) Method of using guava extract and composition including guava extract
WO2007130612A3 (en) Method for obtaining and storing multipotent stem cells
WO2008013966A3 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
WO2004011012A3 (en) Stem cells for treating pancreatic damage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06788441

Country of ref document: EP

Kind code of ref document: A2